Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.

Autor: Taks M; Departments of aClinical Pharmacology bGastroenterology and Hepatology cClinical Chemistry, Catharina Hospital, Eindhoven dDepartment of Clinical Pharmacology, Máxima Medical Center, Veldhoven, The Netherlands., Pijls PA, Derijks LJ, Ten Broeke R, Grouls RJ, Curvers J, Gilissen LP

Publikováno v: European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2017 Feb; Vol. 29 (2), pp. 169-173.

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.

Autor: van den Reek JM; Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Juul.vandenReek@Radboudumc.nl., Pijls PA; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands., Tummers M; Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands., van Riel PC; Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands., Kievit W; Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands., Hoentjen F; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands., de Jong EM; Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2016 Jan; Vol. 74 (1), pp. 177-9.